Differences between clinical and laboratory findings in XXXX with recent diagnosis of @entity1252 according to the positivity of anti-dsDNA by the Crithidia luciliae method.

@entity1 @entity2905 @entity1252 @entity1062
BACKGROUND: Of all anti-dsDNA antibody detection methods, the @entity1062 ( @entity1062 ) is considered to have the highest specificity for @entity1252 ( @entity1252 ). OBJECTIVE: The objective of this report is to evaluate whether the presence of anti-dsDNA antibodies detected by the @entity1062 method is associated with a specific clinical phenotype in recently diagnosed @entity1252 . METHODS: This retrospective cross-sectional study included all @entity1 with newly diagnosed @entity1252 between 1990 and 2011 and followed up in our institution. Demographic, clinical and laboratory findings were assessed. Correlations between positivity of anti-dsDNA by the @entity1062 method, clinical and laboratory data were analyzed. RESULTS: A total of 104 @entity1 were included in the analysis. @entity1 who were positive for anti-dsDNA by the @entity1062 method at the time of diagnosis had (statistically) significantly higher titers of anti-dsDNA by the ELISA method, antinuclear (ANA) and anticardiolipin antibodies, @entity2905 and complement consumption compared with the other two groups. Also they presented significantly more musculoskeletal symptoms at baseline. CONCLUSION: The presence of anti-dsDNA by the @entity1062 method in newly diagnosed @entity1252 was associated with certain markers of increased disease activity. Its use could be a useful biomarker for a specific clinical phenotype suggestive of a more severe involvement at the time of the diagnosis.
